We are exploring new ways to think about and potentially treat serious central nervous system (CNS) disorders. As part of this mission, we conduct clinical trials to determine if our investigational medicines are safe and effective for patients with a particular disease or disorder.
We are motivated by the experiences of patients and caregivers
Patient and caregiver perspectives inspire every aspect of our work. Identifying unmet patient needs drives our research and development focus. We are rethinking care and how it is delivered. We also seek to help increase awareness and improve understanding of CNS disorders. Having patients top of mind keeps us grounded in our purpose — to help improve the well-being of individuals and families impacted by CNS diseases.
Expanded Access Program
We understand that, in some cases, patients with serious diseases or conditions may not be eligible for clinical trials and may not have other treatment options. Under very limited circumstances, we will consider making investigational medicines available for individual patients to treat a serious disease or condition outside of a clinical trial. This type of access is often referred to as “expanded access” or “compassionate use.” For more information, see our Expanded Access Program description.